The rapid therapeutic success of PROTACs and Molecular Glue Degraders has underpinned a surge in new proximity-based modalities with the ability to treat a wide array of previously undruggable diseases. Last year alone there was a 72% increase in the number of induced proximity assets on Beacon by Hanson Wade.
Additionally, with significant funding - from a $186 million partnership between Photys Tx and Novo Nordisk, to the launch of new companies such as General Proximity and Outrun – the induced proximity field is experiencing unprecedented momentum, accelerating the next wave of novel drugs through discovery and translational pipeline for clinical validation.
Coming to San Diego, CA for the first time, the 5th Induced Proximity-Based Drug Discovery Summit returns as your intimate learning and networking setting to cover the depth and breadth of proximity-based drugs from stabilization, phosphorylation and methylation to novel lysosome-based degradation to finally drug the undruggable.
Enabling leaders in biopharma and academia to identify novel MoAs, leverage advanced technologies to find targets more efficiently, and optimize chemical structures for more effective therapeutic agents for a wide range of disease areas. Alongside key strategic updates on DUBTACs, RIPTACs, tPRIMEs, RiboTACs and more, it provides granular technical and scientific insights to overcome challenges in accessing diverse chemical matter and designing selective, potent small molecules of tomorrow.
Join 70+ experts in drug discovery, medicinal chemistry, chemical biology and structural biology from leading companies such as Genentech, Halda Therapeutics and Stablix and gain access to genuinely innovative research from breakthrough companies and academic labs pioneering the next generation of induced proximity-based drugs beyond the ubiquitin proteasome system.
URL:
Brochure: https://go.evvnt.com/2979887-3?pid=263
Prices:
Conference Only (Drug Developer Pricing): USD 2999.00,
Conference Only (Academic Pricing): USD 2599.00,
Conference Only (Service Provider Pricing): USD 3699.00
Speakers: Aaron Frank, Director, Head of Computational and Chemistry, Arrakis Therapeutics, Abhishek Dogra, Director, Medicinal Chemistry and Induced Proximity, A-Alpha Bio, Arpita Sen, Scientist, Biochemistry, A-Alpha Bio, Benjamin Levin, Principal Scientist, Stablix, Craig Blain, Senior Director, RNA Biology, Arrakis Therapeutics, Eric Wang, Professor, Sanford Burnham Prebys Medical Discovery Institute, Hai Rao, Professor, Southern University of Science and Technology, James Mousseau, Director, Chemistry Halda Therapeutics, Jeff Warrington, Principal Scientist, Computational Drug Discovery | Digital Science and Innovation Novo Nordisk, Jun Qi, Associate Professor, Medicine Research Dana-Farber Harvard Cancer Center, Markus Haeberlein, EVP, Discovery Science Parabilis Medicines, Moses Moustakim, Senior Scientist, Chemistry Photys Therapeutics, Peggy Thompson, Vice President and Head of Biology Plexium, Richard Bonneau, Vice President, Drug Discovery, gRED Computational Sciences Genentech, Satoshi Konagai, Investment Lead Astellas Pharma, Seth Carbonneau Senior Principal Scientist Novartis, Sriram Subramaniam, CEO and Founder Gandeeva Therapeutics, Tyzoon Nomanbhoy, Vice President, Chemical Biology Vicinitas Therapeutics
Additionally, with significant funding - from a $186 million partnership between Photys Tx and Novo Nordisk, to the launch of new companies such as General Proximity and Outrun – the induced proximity field is experiencing unprecedented momentum, accelerating the next wave of novel drugs through discovery and translational pipeline for clinical validation.
Coming to San Diego, CA for the first time, the 5th Induced Proximity-Based Drug Discovery Summit returns as your intimate learning and networking setting to cover the depth and breadth of proximity-based drugs from stabilization, phosphorylation and methylation to novel lysosome-based degradation to finally drug the undruggable.
Enabling leaders in biopharma and academia to identify novel MoAs, leverage advanced technologies to find targets more efficiently, and optimize chemical structures for more effective therapeutic agents for a wide range of disease areas. Alongside key strategic updates on DUBTACs, RIPTACs, tPRIMEs, RiboTACs and more, it provides granular technical and scientific insights to overcome challenges in accessing diverse chemical matter and designing selective, potent small molecules of tomorrow.
Join 70+ experts in drug discovery, medicinal chemistry, chemical biology and structural biology from leading companies such as Genentech, Halda Therapeutics and Stablix and gain access to genuinely innovative research from breakthrough companies and academic labs pioneering the next generation of induced proximity-based drugs beyond the ubiquitin proteasome system.
URL:
Brochure: https://go.evvnt.com/2979887-3?pid=263
Prices:
Conference Only (Drug Developer Pricing): USD 2999.00,
Conference Only (Academic Pricing): USD 2599.00,
Conference Only (Service Provider Pricing): USD 3699.00
Speakers: Aaron Frank, Director, Head of Computational and Chemistry, Arrakis Therapeutics, Abhishek Dogra, Director, Medicinal Chemistry and Induced Proximity, A-Alpha Bio, Arpita Sen, Scientist, Biochemistry, A-Alpha Bio, Benjamin Levin, Principal Scientist, Stablix, Craig Blain, Senior Director, RNA Biology, Arrakis Therapeutics, Eric Wang, Professor, Sanford Burnham Prebys Medical Discovery Institute, Hai Rao, Professor, Southern University of Science and Technology, James Mousseau, Director, Chemistry Halda Therapeutics, Jeff Warrington, Principal Scientist, Computational Drug Discovery | Digital Science and Innovation Novo Nordisk, Jun Qi, Associate Professor, Medicine Research Dana-Farber Harvard Cancer Center, Markus Haeberlein, EVP, Discovery Science Parabilis Medicines, Moses Moustakim, Senior Scientist, Chemistry Photys Therapeutics, Peggy Thompson, Vice President and Head of Biology Plexium, Richard Bonneau, Vice President, Drug Discovery, gRED Computational Sciences Genentech, Satoshi Konagai, Investment Lead Astellas Pharma, Seth Carbonneau Senior Principal Scientist Novartis, Sriram Subramaniam, CEO and Founder Gandeeva Therapeutics, Tyzoon Nomanbhoy, Vice President, Chemical Biology Vicinitas Therapeutics
